Quality & Compliance

We dig into the story of Lonza in China, and its new HPAPI expansion in Guangzhou

Advanced analytical technologies now offer the detailed assessments biopharma drug developers need.

How an initiative from EFPIA and a new public database on chemical substances could reduce animal experiments.

With the FDA still behind on inspections, manufacturers need to uncover their own blindspots.

An industry consortium is tackling one of pharma’s biggest drug-related challenges.

Researchers explain how they used video games to explore human behavior when it comes to producing pharma products.

Changes are coming to Annex 1 of the EU’s GMP. What can pharma expect?

Building and managing an advanced therapy collection network is a significant challenge, but there is another route.

To keep biosimilars costs as low as possible, take a good look at your purification and characterization processes.

Simple and efficient systems for continuous monitoring can make all the difference in developing innovative products.